1
|
Emna B, Kmira Z, Hajer BI, Nadia S, Yossra D, Amina B, Yosra BY, Haifa R, Abderrahim K. Acquired hemophilia A following COVID-19 vaccine: a case report. J Med Case Rep 2023; 17:125. [PMID: 36973766 PMCID: PMC10041501 DOI: 10.1186/s13256-023-03850-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2022] [Accepted: 02/26/2023] [Indexed: 03/29/2023] Open
Abstract
BACKGROUND In the literature, reported cases of Acquired hemophilia A (AHA) induced by COVID-19 vaccination occurred after Adenoviral Vector Deoxyribonucleic Acid (DNA)- and SARS-CoV-2 Messenger Ribonucleic acid (mRNA)-Based vaccines. Here, and to the best of our knowledge, we report the first case of AHA occurring after an inactivated Sinovac-coronavac COVID-19 vaccine. CASE PRESENTATION A 69-year-old Tunisian male patient consulted for severe left leg pain limiting physical mobility due to a 5*6 cm large ecchymosis located at the left inner thigh, having spontaneously appeared 5 days prior consultation and without notion of trauma. The patient had no known personal medical history. He had received the second dose of CoronaVac-SinoVac vaccine 30 days prior to consultation. Further physical examination revealed the presence of two other ecchymoses: one at the inner face of the right forearm, starting at the wrist reaching the elbow and the other at the left flank of the abdomen. Diagnosis of AHA was based on clinical presentation and confirmed with prolonged a PTT, Factor VIII deficiency and the presence of an FVIII inhibitor. The patient was successfully treated with corticosteroids and low dose Rituximab. CONCLUSION Clinicians should consider AHA in front of prolonged aPTT with or without spontaneous bleedings even after inactivated virus COVID-19.
Collapse
Affiliation(s)
- Bouselama Emna
- Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia
| | - Zahra Kmira
- Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia
| | - Ben Ismail Hajer
- Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia
| | - Sassi Nadia
- Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia
| | - Dhaha Yossra
- Laboratory of Hematology, Sahloul University Hospital, Sousse, Tunisia
| | - Bouatay Amina
- Laboratory of Hematology, Sahloul University Hospital, Sousse, Tunisia
| | - Ben Youssef Yosra
- Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia
| | - Regaieg Haifa
- Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia
| | - Khelif Abderrahim
- Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia
| |
Collapse
|
2
|
Short-time Safety of the Sinopharm COVID-19 Vaccine in Patients with Hemophilia. ARCHIVES OF CLINICAL INFECTIOUS DISEASES 2022. [DOI: 10.5812/archcid-122097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background: The COVID-19 pandemic, caused by SARS-Cov-2, has affected the care of patients with hemophilia, indicating the necessity of their vaccination. Nevertheless, there are concerns about using anti-SARS-Cov-2 virus vaccines for hemophilic patients, particularly concerning bleeding adverse events. Methods: Following a cross-sectional design, all adult hemophilic patients who received two doses of Sinopharm anti-SARS-Cov-2 virus vaccine in Afzalipour Hospital, Kerman, Iran, during May and June 2021 were recruited. The participants were followed for two weeks after receiving each dose of vaccine. Results: Fifty-one patients with a mean age of 37.07 ± 11.45 years were included, of whom 27 (61.4 %) patients experienced at least one adverse reaction. Pain was the most frequent local adverse event (occurred in 20 (39.2%) and 15 (29.4%) cases after 1st and 2nd doses, respectively). Menometrorrhagia and epistaxis were reported by two and one patients, respectively. Conclusions: Overall Sinopharm anti-SARS-Cov-2 virus vaccine seems to be safe for patients with hemophilia in the short term.
Collapse
|
3
|
Nakamura S, Sugasaki M, Souri M, Akazawa H, Sogawa M, Hori T, Yamagami H, Takishita M, Aihara KI, Abe M, Yasumoto A, Morishita E, Ichinose A. Autoimmune acquired factor XIII/13 deficiency after SARS-CoV-2 mRNA vaccination. Thromb Haemost 2022; 122:1837-1842. [PMID: 35636450 PMCID: PMC9512586 DOI: 10.1055/a-1863-7265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Shingen Nakamura
- Department of Community Medicine and Medical Science, University of Tokushima Graduate School of Biomedical Sciences, Tokushima, Japan
| | - Motoki Sugasaki
- Department of Medical Technology, Tokushima University Hospital, Tokushima, Japan
| | - Masayoshi Souri
- Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan.,The Japanese Collaborative Research Group (JCRG) on Autoimmune Acquired Coagulation Factor Deficiencies, Yamagata, Japan, Yamagata, Japan
| | | | - Maiko Sogawa
- Department of Dermatology, Anan Medical Center, Anan, Japan
| | - Taiki Hori
- Department of Internal Medicine, Anan Medical Center, Anan, Japan
| | - Hiroki Yamagami
- Department of Internal Medicine, Anan Medical Center, Anan, Japan
| | - Makoto Takishita
- Department of Internal Medicine, Anan Medical Center, Anan, Japan
| | - Ken-Ichi Aihara
- Department of Community Medicine and Medical Science, University of Tokushima Graduate School of Biomedical Sciences, Tokushima, Japan
| | - Masahiro Abe
- Department of Hematology, Endocrinology and Metabolism, University of Tokushima Graduate School of Biomedical Sciences, Tokushima, Japan
| | - Atsushi Yasumoto
- Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan
| | - Eriko Morishita
- Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan
| | - Akitada Ichinose
- Department of Molecular Patho-Biochemistry, Yamagata University, Yamagata, Japan.,The Japanese Collaborative Research Group (JCRG) on Autoimmune Acquired Coagulation Factor Deficiencies, Yamagata, Japan, Yamagata, Japan
| |
Collapse
|
4
|
Weber C, Rigby A, Lip GYH. Thrombosis and Haemostasis 2021 Editors' Choice Papers. Thromb Haemost 2022; 122:163-170. [PMID: 35038760 DOI: 10.1055/s-0041-1741072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Affiliation(s)
- Christian Weber
- Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany.,German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.,Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands
| | - Anne Rigby
- Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany
| | - Gregory Y H Lip
- Liverpool Centre for Cardiovascular Science, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom.,Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| |
Collapse
|